VBI Vaccines Reveals Updated Overall Survival Data From Brain Cancer Vaccine Trial
VBI Vaccines Inc (NASDAQ: VBIV) has presented
FDA Approves VBI Vaccines’ 3-Antigen Hepatitis B Vaccine
The FDA has approved VBI Vaccines Inc's (NASDAQ:
The Week Ahead In Biotech (Nov. 28-Dec. 4): FDA Decisions For VBI Vaccines, BeyondSpring, CTI Biopharma And Merck Take The Spotlight In A Light Calendar Week
Biotech stocks advanced in the week ending Nov. 26, as a late-week surge on the back of news about a new COVID-19 variant, named Omicron, helped mitigate the losses notched earlier in the holiday-shortened week.
Attention Biotech Investors: Mark Your Calendar For November PDUFA Dates
The loaded Prescription Drug User Fee Act (PDUFA) calendar for October produced mixed outcomes.
PDUFA dates are key binary events for biotech stocks that can move the needle in a big way. These are the dates by which the Food and Drug Administration is required to announce its decision regarding approvability/non-approvability of drugs.
VBI Vaccines Highlights Publication Of Results From Pivotal Phase 3 Study, CONSTANT, Of VBI’s Prophylactic 3-Antigen Hepatitis B Vaccine Candidate In The Journal Of The American Medical Association Network Open
Publication title: "Immunogenicity and safety of a 3-Antigen Hepatitis B Vaccine vs a Single-Antigen Hepatitis B Vaccine; A Phase 3 Randomized Clinical Trial"
The Phase 3 study, in 2,838 adults age
VBI Vaccines Announces Preclinical Data And Initiation Of VBI-2905 Clinical Study Targeting Broadened Immunity Against COVID-19 And Variants Of Concern
- New preclinical data demonstrate VBI-2905 induced robust neutralizing and antibody binding activity, as a 2-dose course and as a single booster dose, against COVID-19 and variants of concern including Beta and Delta
-
VBI Vaccines Reports New CPT Code Issued For 3-Antigen Prophylactic Hepatitis B Vaccine
VBI Vaccines Inc. (NASDAQ:VBIV) (VBI), a biopharmaceutical company driven by immunology in the pursuit of powerful prevention and treatment of disease, today reported that the American Medical Association (AMA) Current
VBI Vaccines Stock Is Trading Higher On Encouraging Data From COVID-19 Vaccine Candidate Trial
VBI Vaccines Inc (NASDAQ:VBIV) has announced positive Phase 1 data from its Phase 1/2 trial evaluating its enveloped virus-like particle (eVLP)…
VBI Vaccines Announces Initial Phase 1 Data For Its eVLP Vaccine Candidate Against COVID-19; Says After Two Doses, VBI-2902a ‘induced neutralization titers in 100% of participants’
The Phase 1 portion of the ongoing Phase 1/2 study evaluated one- and two-dose regimens of 5µg of eVLP candidate, VBI-2902a, in 61 healthy adults age 18-54 years
After two doses, VBI-2902a induced neutralization